Form 4: Liquidia CMO Sells Over 35,000 Shares

Liquidia Corp's Chief Medical Officer, Rajeev Saggar, reported the sale of 35,365 shares of common stock for approximately $1.28 million.

Summary

• Rajeev Saggar, Chief Medical Officer of Liquidia Corp (LQDA), sold 35,365 shares of common stock.
• The transaction occurred on March 13, 2026, at a volume-weighted average price of $36.3024 per share.
• The total value of the shares sold is approximately $1,284,000.
• Following the sale, Dr. Saggar beneficially owns 174,473 shares of Liquidia Corp common stock.
• The sale was executed pursuant to a Rule 10b5-1 pre-planned trading arrangement.
• The remaining beneficial ownership includes 20,833 unvested RSUs from a January 2023 grant, 28,246 unvested RSUs from a January 2024 grant, 53,835 unvested RSUs from a January 2025 grant, 32,955 unvested RSUs from a January 2026 grant, and 2,213 shares acquired under the Liquidia Corporation 2020 Employee Stock Purchase Plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral to slightly negative event. While the sale was pre-planned under a 10b5-1 arrangement, reducing the immediate negative signal, it still represents an insider reducing their direct equity stake.

Positives

• The sale was conducted under a Rule 10b5-1 plan, indicating it was pre-scheduled and not necessarily a reaction to recent negative company news.
• The Chief Medical Officer retains a significant beneficial ownership of 174,473 shares, aligning his interests with shareholders.

Negatives

• An insider sale, particularly by a Chief Medical Officer, can sometimes be perceived as a lack of confidence in the company's near-term prospects, even if pre-planned.
• The sale represents a reduction in direct ownership by a key executive.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider transactions, particularly sales, are closely watched by investors for signals regarding management's confidence. While a Rule 10b5-1 plan mitigates the immediate negative interpretation, it still represents a reduction in direct equity exposure by a key executive.

Related Party Transactions

• Sale of 35,365 shares of Liquidia Corp common stock by Chief Medical Officer Rajeev Saggar.

Stakeholder Impact

• Shareholders: May view the insider sale with caution, potentially interpreting it as a signal, despite the 10b5-1 plan.

Key Dates

Recommendation

While an insider sale can sometimes be a negative signal, the fact that it was executed under a Rule 10b5-1 plan suggests it was a pre-scheduled liquidity event rather than a reaction to new, undisclosed negative information. Given the significant remaining beneficial ownership, a single Form 4 transaction typically warrants a "hold" recommendation, as it's one data point among many for a seasoned investor.

Keywords

Liquidia Corp, LQDA, Rajeev Saggar, Chief Medical Officer, insider trading, stock sale, Form 4, 10b5-1 plan, equity disposition